SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs Q3 earnings report is the dominant focus, with traders debating whether a strong report and raised guidance can overcome elevated expectations amid a broader AI-stock pullback. Bulls point to continued AI growth, while bears warn that a beat may not be enough to prevent profit-taking or valuation pressure.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Attention centers on Zevras quarterly results and the pending CHMP re-examination of MIPLYFFA, with the FDAs follow-up on celiprolol also viewed as a potential catalyst. Traders see U.S. MIPLYFFA growth as a support, but debate whether European regulators will reverse their earlier negative opinion, while some express frustration with management and the stocks volatility.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anticipation for QUILT-2.005 topline results on ANKTIVA plus BCG in BCG-naive bladder cancer dominates discussion, with traders debating whether the data will support broader first-line use after ANKTIVAs expanded bladder-cancer approval. Many are bullish on the potential commercial expansion and upcoming earnings, while others cite execution and competition concerns and blame short selling for recent weakness.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is caught in a semiconductor selloff as traders question whether hyperscalers massive AI spending will generate sufficient returns, with concerns about customer concentration and financing structures weighing on sentiment. Bulls counter that Anthropics filing and bank-backed financing for Broadcom equipment support future demand, while others see the deals guarantees as added risk.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL immunotherapy data presented at ESMO, including early neoadjuvant colon cancer responses and sarcoma activity, are driving discussion. Bulls view the findings as promising validation, while skeptics point to small, nonrandomized studies and ongoing concerns about execution and dilution.

Amp (AMP) is a cryptocurrency launched in 2020and operates on the Ethereum platform. Amp has a current supply of 99,720,267,351.28921674 with 89,781,193,103.18022 in circulation. The last known price of Amp is 0.00066971 USD and is down -6.50 over the last 24 hours. It is currently trading on 193 active market(s) with $8,745,522.76 traded over the last 24 hours. More information can be found at https://amp.xyz.

AMP Token

A sharp, high-volume move in AMP has traders debating whether it marks a sustained breakout or another short-lived pump-and-dump; some also point to the Flexa payments and Anvil collateral thesis as longer-term support, though no new catalyst is clearly confirmed. Skeptics cite AMPs history of fading rallies and concerns about project execution.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is under pressure after its latest earnings despite beating expectations and raising its outlook, as traders focus on slower cloud net-new ARR growth and cautious second-half guidance. Bulls view the pullback as profit-taking after a strong run and point to continued business growth, while skeptics argue high expectations and the guidance outlook warrant a lower valuation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results have focused attention on heavy AI infrastructure spending and its impact on cash flow, despite accelerating AWS growth that fell short of some investors expectations. Traders are split between worrying that the spending and financing burden may outweigh near-term returns and viewing the post-earnings selloff as an overreaction to strong cloud demand.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

A stronger-than-expected Q3 report and raised full-year outlook are supporting bullish attention, alongside Mercks Moderna-partnered melanoma vaccine meeting Phase 3 endpoints with Keytruda. Traders see potential oncology-platform value, but debate whether the results meet high expectations and how much upside the vaccine may add for Merck.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on the Dows relative strength versus tech-heavy indexes and possible rotation into blue-chip stocks, alongside technical support and resistance. Traders are split between expecting further gains and warning of a pullback, with rising yields, inflation concerns, and Iran-related oil risks adding to market uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Dell Technologies (DELL) Stock Outpacing Its Computer and Technology Peers This Year?

Here is how Dell Technologies (DELL) and CDW (CDW) have performed compared to their sector so far this year.

CDW to Announce Third Quarter 2026 Results on November 4

CDW Corporation (Nasdaq: CDW) announced today that it will host a webcast conference call to discuss its third quarter 2026 results on Wednesday, November 4, 2026, at 7:30 a.m. CT/8:30 a.m. ET. A live webcast (audio with slides) of the conference call will be accessible at investor.CDW.com. The...

CDW Appoints Sam Balaji to Board of Directors

CDW (Nasdaq: CDW), the strategic end-to-end technology partner that turns customer ambition into outcomes, today announced the appointment of Sam Balaji to its Board of Directors, effective October 15, 2026. Balaji brings more than three decades of experience in technology, advisory and global...

AVT Surges 88.5% in a Year: Should You Buy, Sell or Hold the Stock?

Avnet's AI infrastructure demand, record IP&E sales and expanding Farnell margins support its growth outlook, while its valuation remains below the industry average.

TD SYNNEX Surges 78% YTD: Is the SNX Stock Still Worth Buying?

SNX's 78% YTD rally, surging AI infrastructure demand, robust earnings growth and discounted valuation make the stock an attractive buy. Read on to learn why.

Can CDW Corporation Restore Margin Momentum in the Second Half?

CDW enters the second half of 2026 targeting stronger operating leverage as expense discipline offsets continued gross-margin pressure from business mix.

CDW's Buyback Pace Jumps: Can Stronger Cash Flow Sustain Returns?

CDW accelerated 2026 shareholder returns as buybacks surged, while second-half cash flow hinges on inventory normalization and working-capital improvement.

Is the Options Market Predicting a Spike in CDW Stock?

Investors need to pay close attention to CDW stock based on the movements in the options market lately.

CDW Completes Acquisition of Lovelytics

CDW (Nasdaq: CDW), the strategic end-to-end technology partner that turns customer ambition into outcomes, today announced that it has completed its previously announced acquisition of Lovelytics, a leading data and AI services firm and a member of the Databricks Brickbuilder Partner Network. The...

CDW Canadas AI Workplace Trends Report Finds Canadian Organizations Entering New Phase of AI Maturity as Agentic AI Gains Ground

Today, CDW Canada, the strategic end-to-end technology partner that turns customer ambition into outcomes, released new research exploring how Canadian organizations are moving from artificial intelligence (AI) deployment to realizing business value. The report, Canadas AI Workplace Evolution from...

CDW Corp. engages in the provision of information technology solutions to small, medium, and large business, government, education, and healthcare customers. It operates through the following segments: Commercial, Government, and Education. The Commercial segment consists of corporate, financial services, and healthcare customers in the U.S. The Government segment includes federal, state, and local agencies in the U.S. The Education segment consists of primary, secondary, and higher education institutions in the U.S. The company was founded by Michael P. Krasny in 1984 and is headquartered in Vernon Hills, IL.

CDW Corp

CDW Stock Jumps Nearly 6% — Why Morgan Stanley Is Growing More Optimistic On This IT Play

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Morgan Stanley upgraded CDW to ‘Overweight’ and raised its price target as well.</li><li>The firm reportedly says that while CDW has lagged peers, the “IT disruption” concerns are overstated, with positive estimate revisions expected to return in the second half of 2026.</li><li>A $1-billion share buyback, announced in late May, could provide additional upside for the stock, according to Morgan Stanley.</li></ul>Shares of CDW Corp (CDW) jumped nearly 6% in intraday trading on Tuesday after Morgan Stanley turned bullish on the hardware and software company. The bank said the stock is positioned to outperform after a period of relative underperformance and offers an attractive way for investors to gain exposure to the enterprise server market.At the time of writing, the <a href="https://stocktwits.com/symbol/CDW">CDW stock</a> was trading about 5.5% higher.<h2 class="st-heading-2">CDW Upgrade Backed By Strong Server Demand</h2>Morgan Stanley analyst Erik Woodring upgraded CDW to ‘Overweight’ from ‘Equal Weight,’ and raised its price target to $170 from $142, implying about 32% upside over the stock’s Monday closing price.The firm said enterprise server demand is “proving far more inelastic than expected” due to compute shortages, refresh activity, and growing AI-related infrastructure, according to TheFly. Morgan Stanley views CDW as one of the most attractive ways to play server demand upside.While CDW has been the “clear laggard of the group,” the bank said the “IT disruption” thesis is overstated, with positive estimate revisions expected to return in the second half of 2026.<h2 class="st-heading-2">CDW Valuation Seen As ‘Compelling Relative To Peers’</h2>Morgan Stanley said CDW’s “valuation remains compelling relative to peers.” The firm said the “IT disruption” thesis surrounding the company is overstated and that positive estimate revisions and a return to operating leverage in the second half of the year should help address those concerns, reported CNBC.CDW has faced pressure from concerns that rising inflation and broader artificial intelligence adoption could hurt growth. Weakness in software revenue has also weighed on profit margins, stated the CNBC report.Despite those challenges, Morgan Stanley said more than 20% of the company’s revenue has been driven by stronger-than-expected demand for servers, storage and networking products.Morgan Stanley also highlighted CDW’s incremental $1 billion share repurchase plan announced in late May, saying the buyback could provide additional upside for the stock.<h2 class="st-heading-2">CDW Stock: What Retail Says</h2>Stocktwits sentiment on CDW was ‘neutral.’ Over the past 30 days, message volume around the stock has risen by 200%.Morgan Stanley’s positive view aligns with broader Wall Street sentiment. According to Koyfin data, seven of the 10 analysts covering CDW rate the stock a ‘Buy’ or ‘Strong Buy.’Year-to-date, <a href="https://stocktwits.com/symbol/CDW">CDW shares</a> have fallen by over 8%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/meta-expands-299-smart-glasses-lineup-as-it-challenges-apple-s-ar-ambitions-stock-gains-nearly-1-5/cZKwBjiR7ar">META Expands $299 Smart Glasses Lineup As It Challenges Apple’s AR Ambitions — Stock Gains Nearly 1.5%</a>

CDW Corporation company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Shares of CDW Corp (CDW) jumped nearly 6% in intraday trading on Tuesday after Morgan Stanley turned bullish on the hardware and software company. 

The Wall Street bank says concerns around AI disruption and weak software sales have created an attractive entry point in CDW.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CDW News